Furthermore, hormone receptor status, namely ER receptor positivity, is linked to the possible effectiveness of PI3K inhibitors in ER+ breast cancer since PIK3CA mutations are more prevalent in this subtype [17]. This evidence concerns the gene PIK3CA and breast carcinoma.